Multiple myeloma: understanding the impact of the disease
Patricia Jean Smith Research fellow, Department of Applied Biological Sciences, City University, St Bartholomew School of Nursing and Midwifery, London
Carol Lynn Cox Acting deputy director, Institute of Health Sciences, City University, St Bartholomew School of Nursing and Midwifery, London
Daniel Kelly Reader in cancer and palliative care, Middlesex University, London
Multiple myeloma is a cancer of the red bone marrow and despite modern treatments, such as high dose chemotherapy and stem cell transplants, it remains incurable with a median survival of between three to four years (Hoffbrand et al 2001, Bradwell 2003). The aim of this article is to increase awareness and understanding of this relatively unknown cancer.
Cancer Nursing Practice.
6, 1, 25-28.
doi: 10.7748/cnp2007.02.6.1.25.c4189
Want to read more?
Already have access? Log in
or
3-month trial offer for £5.25/month
Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
- Unlimited access to all 10 RCNi Journals
- RCNi Learning featuring over 175 modules to easily earn CPD time
- NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
- Personalised newsletters tailored to your interests
- A customisable dashboard with over 200 topics
Subscribe
Alternatively, you can purchase access to this article for the next seven days.
Buy now
Are you a student? Our student subscription has content especially for you.
Find out more